Your browser is no longer supported. Please, upgrade your browser.
RGEN Repligen Corporation daily Stock Chart
Repligen Corporation
Index- P/E262.49 EPS (ttm)0.58 Insider Own0.80% Shs Outstand52.38M Perf Week1.23%
Market Cap8.12B Forward P/E109.12 EPS next Y1.40 Insider Trans-32.70% Shs Float48.67M Perf Month18.73%
Income30.90M PEG9.91 EPS next Q0.28 Inst Own88.80% Short Float3.51% Perf Quarter24.35%
Sales302.50M P/S26.85 EPS this Y19.10% Inst Trans-1.01% Short Ratio2.58 Perf Half Y50.77%
Book/sh21.00 P/B7.27 EPS next Y9.63% ROA2.20% Target Price159.43 Perf Year63.02%
Cash/sh10.54 P/C14.49 EPS next 5Y26.50% ROE2.90% 52W Range72.32 - 159.97 Perf YTD65.16%
Dividend- P/FCF176.55 EPS past 5Y12.10% ROI2.00% 52W High-4.50% Beta1.15
Dividend %- Quick Ratio13.90 Sales past 5Y33.60% Gross Margin56.90% 52W Low111.24% ATR5.25
Employees761 Current Ratio15.50 Sales Q/Q23.80% Oper. Margin13.10% RSI (14)68.83 Volatility3.41% 3.50%
OptionableYes Debt/Eq0.00 EPS Q/Q80.30% Profit Margin10.20% Rel Volume0.70 Prev Close154.67
ShortableYes LT Debt/Eq0.22 EarningsJul 30 BMO Payout0.00% Avg Volume661.93K Price152.77
Recom1.60 SMA209.52% SMA5018.91% SMA20044.34% Volume460,718 Change-1.23%
Jun-30-20Reiterated H.C. Wainwright Buy $143 → $151
May-07-20Reiterated H.C. Wainwright Buy $100 → $143
Mar-23-20Reiterated H.C. Wainwright Buy $110 → $100
Nov-15-19Initiated Stifel Buy
Nov-01-19Upgrade First Analysis Sec Outperform → Strong Buy $107 → $110
Oct-15-19Initiated SVB Leerink Outperform $100
Aug-28-19Reiterated First Analysis Sec Outperform $95 → $107
Aug-23-19Resumed Stephens Overweight
Jul-22-19Upgrade H.C. Wainwright Neutral → Buy $110
Dec-17-18Upgrade CL King Neutral → Buy
Nov-12-18Downgrade CL King Buy → Neutral
Sep-26-18Initiated H.C. Wainwright Neutral $49
Dec-08-17Initiated Citigroup Buy $45
Dec-05-17Initiated JP Morgan Overweight $42
Nov-13-17Initiated CL King Buy
Oct-02-17Upgrade First Analysis Sec Equal-Weight → Overweight $47
Jul-21-17Initiated William Blair Outperform
Feb-13-17Upgrade Piper Jaffray Neutral → Overweight
Feb-22-16Initiated Craig Hallum Buy
Nov-06-15Downgrade Jefferies Buy → Hold
Aug-03-20 02:33PM  
Jul-31-20 02:44PM  
Jul-30-20 10:28AM  
Jul-23-20 03:27PM  
Jul-22-20 11:40AM  
Jul-15-20 07:30AM  
Jul-08-20 01:23PM  
Jul-03-20 11:40AM  
Jun-29-20 07:30AM  
Jun-18-20 03:32PM  
Jun-17-20 11:40AM  
Jun-15-20 06:14PM  
Jun-12-20 08:36AM  
Jun-05-20 11:31AM  
May-28-20 11:40AM  
May-27-20 09:15AM  
May-13-20 12:20PM  
May-08-20 10:23AM  
May-06-20 11:02PM  
May-05-20 10:19AM  
Apr-29-20 12:33PM  
Apr-23-20 02:22PM  
Apr-22-20 04:22PM  
Apr-21-20 04:31PM  
Apr-11-20 10:15AM  
Apr-05-20 09:03PM  
Apr-01-20 06:00AM  
Mar-21-20 11:30AM  
Mar-19-20 04:17PM  
Mar-12-20 10:58AM  
Feb-28-20 11:10AM  
Feb-27-20 07:30AM  
Feb-21-20 10:32AM  
Feb-20-20 11:50PM  
Feb-19-20 12:45PM  
Feb-13-20 12:31PM  
Feb-06-20 07:30AM  
Feb-04-20 06:41PM  
Jan-30-20 11:10AM  
Jan-24-20 10:15AM  
Jan-17-20 08:45AM  
Jan-10-20 12:43PM  
Jan-08-20 04:06PM  
Jan-07-20 07:30AM  
Dec-11-19 02:04PM  
Dec-09-19 11:30AM  
Dec-08-19 07:11PM  
Dec-06-19 12:45PM  
Dec-04-19 12:00PM  
Dec-02-19 04:32PM  
Nov-14-19 09:30AM  
Nov-06-19 04:08AM  
Nov-01-19 02:49PM  
Oct-31-19 09:15AM  
Oct-30-19 11:49AM  
Oct-24-19 03:34PM  
Oct-23-19 10:29AM  
Oct-03-19 07:54PM  
Sep-30-19 11:12AM  
Sep-24-19 05:38PM  
Sep-23-19 06:41AM  
Sep-14-19 06:31AM  
Sep-11-19 07:15PM  
Sep-09-19 02:19PM  
Sep-06-19 06:00PM  
Aug-30-19 06:47AM  
Aug-28-19 07:11AM  
Aug-27-19 03:16PM  
Aug-16-19 07:11AM  
Aug-08-19 10:13AM  
Aug-05-19 10:39AM  
Aug-02-19 11:54AM  
Aug-01-19 12:02PM  
Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA kits, which are analytical test kits to quantitate the proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber module-bag-tubing sets. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RYAN THOMAS F JRDirectorJul 31Option Exercise67.712,109142,8004,559Aug 04 07:50 PM
RYAN THOMAS F JRDirectorJul 31Sale151.903,095470,1291,464Aug 04 07:50 PM
DAWES KAREN ADirectorJun 18Sale115.2018,7052,154,851100,734Jun 22 04:42 PM
Hunt AnthonyChief Executive OfficerMay 21Option Exercise24.1050,0391,206,140277,194May 26 09:27 PM
Hunt AnthonyChief Executive OfficerMay 21Sale139.7746,9536,562,409230,241May 26 09:27 PM
DAWES KAREN ADirectorMay 20Sale139.4451772,093119,439May 21 09:08 PM
BARTHELEMY NICOLASDirectorMay 18Option Exercise67.712,109142,8005,673May 26 09:24 PM
BARTHELEMY NICOLASDirectorMay 18Sale142.533,009428,8732,664May 26 09:24 PM
DAWES KAREN ADirectorMay 18Sale137.781,600220,448119,956May 19 08:46 PM
KURIYEL RALFSenior VP, R&DMay 15Sale140.6943561,20026,089May 19 08:54 PM
Snodgres JonChief Financial OfficerMay 15Sale140.4366092,68432,267May 19 08:47 PM
KURIYEL RALFSenior VP, R&DMay 13Option Exercise33.268,000266,04034,524May 15 05:37 PM
Snodgres JonChief Financial OfficerMay 13Option Exercise30.7512,194374,95648,321May 15 05:41 PM
KURIYEL RALFSenior VP, R&DMay 13Sale127.808,0001,022,37326,524May 15 05:37 PM
Snodgres JonChief Financial OfficerMay 13Sale128.7415,3941,981,87532,927May 15 05:41 PM
BARTHELEMY NICOLASDirectorApr 22Option Exercise42.071,65269,5005,725Apr 24 05:22 PM
BARTHELEMY NICOLASDirectorApr 22Sale109.992,688295,6533,037Apr 24 05:22 PM
DAWES KAREN ADirectorApr 21Option Exercise3.3011,80038,940120,834Apr 22 06:07 PM
DAWES KAREN ADirectorApr 20Option Exercise3.308,20027,060121,234Apr 22 06:07 PM
DAWES KAREN ADirectorApr 20Sale104.5712,2001,275,717109,034Apr 22 06:07 PM
BARTHELEMY NICOLASDirectorApr 03Option Exercise42.071,65269,5006,761Apr 06 07:34 PM
BARTHELEMY NICOLASDirectorApr 03Sale99.992,688268,7734,073Apr 06 07:34 PM
Cox JohnDirectorMar 24Sale96.721,858179,706923Mar 26 07:31 PM
Cox JohnDirectorMar 18Option Exercise24.3726,736651,60329,517Mar 20 04:25 PM
Cox JohnDirectorMar 18Sale95.2726,7362,547,0352,781Mar 20 04:25 PM
RYAN THOMAS F JRDirectorMar 16Option Exercise40.421,00040,4152,923Mar 18 05:10 PM
RYAN THOMAS F JRDirectorMar 16Sale91.481,00091,4801,923Mar 18 05:10 PM
RYAN THOMAS F JRDirectorMar 04Option Exercise41.704,796200,0156,719Mar 05 05:53 PM
Cox JohnDirectorMar 04Option Exercise12.9110,000129,10012,781Mar 05 05:52 PM
Hunt AnthonyChief Executive OfficerMar 04Sale90.1312,3001,108,599230,241Mar 05 05:50 PM
Snodgres JonChief Financial OfficerMar 04Sale90.391,04594,45836,127Mar 05 05:53 PM
RYAN THOMAS F JRDirectorMar 04Sale88.824,796425,9811,923Mar 05 05:53 PM
Cox JohnDirectorMar 04Sale93.3910,000933,9002,781Mar 05 05:52 PM
KURIYEL RALFSenior VP, R&DMar 04Sale90.762,555231,88826,524Mar 05 05:53 PM
KURIYEL RALFSenior VP, R&DMar 03Sale88.3545039,75829,079Mar 05 05:53 PM
RYAN THOMAS F JRDirectorMar 03Sale85.722,225190,7271,923Mar 05 05:53 PM
Snodgres JonChief Financial OfficerMar 03Sale88.1861053,79037,172Mar 05 05:53 PM
Hunt AnthonyChief Executive OfficerMar 03Sale88.222,190193,194242,541Mar 05 05:50 PM
Snodgres JonChief Financial OfficerFeb 26Sale86.221,10094,83731,096Feb 27 05:39 PM
Hunt AnthonyChief Executive OfficerFeb 26Sale86.513,475300,627226,148Feb 27 05:39 PM
KURIYEL RALFSenior VP, R&DFeb 26Sale86.6019516,88726,313Feb 27 05:38 PM
Hunt AnthonyChief Executive OfficerFeb 25Option Exercise25.0321,945549,190231,148Feb 27 05:39 PM
Hunt AnthonyChief Executive OfficerFeb 25Sale91.5611,7351,074,447219,413Feb 27 05:39 PM
Cox JohnDirectorFeb 24Sale92.814,455413,4552,781Feb 26 04:27 PM
DAWES KAREN ADirectorFeb 21Sale98.704,000394,793113,034Feb 24 05:51 PM
Snodgres JonChief Financial OfficerDec 05Option Exercise25.273,95799,98032,196Dec 09 04:17 PM
Hunt AnthonyChief Executive OfficerSep 19Option Exercise16.5520,000331,000223,013Sep 23 06:02 PM
Hunt AnthonyChief Executive OfficerSep 19Sale82.893,600298,390219,413Sep 23 06:02 PM
Hunt AnthonyChief Executive OfficerSep 09Sale82.4012,094996,521203,013Sep 11 04:58 PM
ASRT Assertio Holdings, Inc. daily Stock Chart
Assertio Holdings, Inc.
Index- P/E- EPS (ttm)-1.97 Insider Own3.40% Shs Outstand70.94M Perf Week-12.99%
Market Cap98.65M Forward P/E5.22 EPS next Y0.15 Insider Trans-0.37% Shs Float61.33M Perf Month-4.44%
Income-161.70M PEG- EPS next Q-0.03 Inst Own64.80% Short Float2.52% Perf Quarter-1.84%
Sales192.50M P/S0.51 EPS this Y-634.30% Inst Trans19.95% Short Ratio1.03 Perf Half Y-48.45%
Book/sh1.18 P/B0.66 EPS next Y36.36% ROA-27.90% Target Price- Perf Year-72.11%
Cash/sh- P/C- EPS next 5Y25.00% ROE-110.00% 52W Range0.55 - 2.92 Perf YTD-37.31%
Dividend- P/FCF2.69 EPS past 5Y-28.50% ROI-39.80% 52W High-73.16% Beta2.18
Dividend %- Quick Ratio1.50 Sales past 5Y-10.10% Gross Margin95.70% 52W Low42.47% ATR0.08
Employees125 Current Ratio1.50 Sales Q/Q-63.90% Oper. Margin-55.90% RSI (14)38.54 Volatility10.01% 9.10%
OptionableYes Debt/Eq0.69 EPS Q/Q360.70% Profit Margin-84.00% Rel Volume2.57 Prev Close0.94
ShortableYes LT Debt/Eq0.00 EarningsAug 07 BMO Payout- Avg Volume1.50M Price0.78
Recom2.00 SMA20-14.41% SMA50-13.89% SMA200-16.46% Volume3,871,432 Change-16.19%
Nov-30-18Downgrade Mizuho Buy → Neutral
Aug-07-20 09:35AM  
Aug-06-20 03:50PM  
Jul-31-20 12:30PM  
Jul-30-20 06:30AM  
Jul-28-20 04:30PM  
Jul-27-20 05:00PM  
Jul-24-20 12:01PM  
Jul-20-20 06:02AM  
Jul-16-20 04:45PM  
Jul-08-20 07:00AM  
Jun-30-20 11:50PM  
Jun-24-20 06:27PM  
May-22-20 07:24AM  
May-21-20 06:30AM  
May-20-20 06:20PM  
May-17-20 08:09AM  
May-11-20 10:35AM  
May-08-20 10:41PM  
May-06-20 12:30PM  
Apr-30-20 12:00PM  
Apr-20-20 05:08PM  
Apr-08-20 04:05PM  
Apr-02-20 06:24AM  
Mar-17-20 11:41AM  
Mar-16-20 06:45PM  
Mar-11-20 01:01AM  
Mar-09-20 05:55PM  
Mar-08-20 04:14PM  
Mar-02-20 05:30PM  
Feb-26-20 12:30PM  
Feb-24-20 10:33AM  
Feb-19-20 08:00AM  
Feb-17-20 06:00AM  
Feb-14-20 08:23AM  
Feb-13-20 04:05PM  
Feb-07-20 07:32AM  
Feb-06-20 04:01PM  
Feb-04-20 05:45PM  
Jan-29-20 05:45PM  
Jan-22-20 11:30AM  
Jan-15-20 05:45PM  
Jan-13-20 11:40AM  
Jan-09-20 05:45PM  
Jan-08-20 10:18AM  
Jan-07-20 09:51AM  
Dec-27-19 11:40AM  
Dec-23-19 12:00PM  
Dec-19-19 06:40AM  
Dec-13-19 03:07PM  
Dec-12-19 07:50AM  
Dec-10-19 11:40AM  
Nov-26-19 02:29PM  
Nov-13-19 12:58PM  
Nov-07-19 11:26AM  
Nov-06-19 07:45PM  
Nov-04-19 06:05AM  
Oct-30-19 06:35PM  
Oct-23-19 09:05AM  
Oct-22-19 07:51AM  
Oct-21-19 09:05AM  
Oct-13-19 04:33PM  
Oct-05-19 09:54AM  
Sep-30-19 12:35PM  
Sep-26-19 08:00AM  
Sep-24-19 05:38PM  
Sep-20-19 09:40AM  
Sep-09-19 09:50AM  
Sep-05-19 11:05AM  
Sep-04-19 09:30AM  
Aug-20-19 08:00AM  
Aug-19-19 09:30AM  
Aug-12-19 09:15PM  
Aug-09-19 09:28AM  
Aug-08-19 11:24PM  
Aug-07-19 07:35PM  
Aug-06-19 03:22PM  
Jul-31-19 10:36AM  
Jul-26-19 09:30AM  
Jul-17-19 04:05PM  
Jul-01-19 08:39AM  
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The company offers Gralise (gabapentin), a once daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; and Zipsor (diclofenac potassium liquid filled capsules), a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain. It also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to require daily, around-the-clock, and long term opioid treatment, including neuropathic pain related to diabetic peripheral neuropathy in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, the company offers long-acting cosyntropin, an alcohol-free formulation of synthetic adrenocorticotropic hormone. Assertio Therapeutics, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAWES KAREN ADirectorMay 08Sale0.7915,83412,53184,589May 11 08:23 PM
Bukofzer StanSVP, Chf Scitfc & Tech OfficerApr 02Option Exercise0.0025,370070,349Apr 03 06:50 PM
Galeota James JRDirectorMar 30Option Exercise0.0012,492012,492Mar 31 07:32 PM
Mason Heather LDirectorFeb 18Option Exercise0.0014,394014,394Feb 19 05:00 PM
Peisert Daniel A.SVP and CFOFeb 12Option Exercise0.0027,5880112,753Feb 12 06:41 PM
Bukofzer StanSVP, Chf Scitfc & Tech OfficerFeb 12Option Exercise0.0027,588054,524Feb 12 06:40 PM
HIGGINS ARTHUR JDirector, President and CEOFeb 12Option Exercise0.0097,4120275,747Feb 12 06:41 PM
HIGGINS ARTHUR JDirector, President and CEOFeb 06Option Exercise0.0062,3990199,925Feb 06 05:49 PM
Peisert Daniel A.SVP and CFOFeb 06Option Exercise0.006,700087,483Feb 06 05:49 PM
HIGGINS ARTHUR JDirector, President and CEODec 01Option Exercise0.0034,8600147,739Dec 02 05:20 PM
Peisert Daniel A.SVP and CFODec 01Option Exercise0.008,359083,232Dec 02 05:20 PM
HIGGINS ARTHUR JDirector, President and CEONov 12Buy0.7325,00018,250112,879Nov 12 04:36 PM
Peisert Daniel A.SVP and CFONov 11Buy0.7310,0007,25974,873Nov 12 04:36 PM
STAPLE PETER DDirectorNov 11Buy0.7113,9009,91113,900Nov 12 04:36 PM